Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
renal cancer
Biotech
Merck backs up Peloton buyout with promising kidney cancer data
Merck’s recently acquired HIF-2α inhibitor curbed tumor growth in 43% of patients with kidney cancer linked to a particular genetic condition.
Amirah Al Idrus
May 13, 2020 5:00pm
New cancer drug targets emerge from massive protein analysis
Dec 13, 2019 8:20am
Could even more cancer patients benefit from PARP inhibitors?
Jul 16, 2018 12:37pm
Lilly boosts immuno-oncology pipeline with $1.6B Armo buy
May 10, 2018 10:38am
Novartis offloads failed cancer drug to Oncology Venture
Apr 10, 2018 9:15am
Incyte's claims that BMS IDO med stolen set for trial hearing
Oct 16, 2017 8:38am
